Stock Events

Stock Events

Absci 

$9.99
189
+$1.14+12.88% Wednesday 19:59
+$0.01+0.06%Wednesday 23:57After hours

Statistics

Day High
10
Day Low
9.99
52W High
12.06
52W Low
2.24
Volume
64,051
Avg. Volume
-
Mkt Cap
1.71B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.25
-0.23
-0.21
-0.19
Expected EPS
-0.190114
Actual EPS
N/A

Financials

-4,113.68%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.8MRevenue
-115.18MNet Income

Analyst Ratings

13.00Average Price Target
The highest estimate is 16.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABSI. It's not an investment recommendation.
NVIDIA
50
NVDA
Amazon
40
AMZN
Palantir Technologies
39
PLTR
Microsoft
31
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Twist Bioscience
TWST
Mkt Cap7.44B
Twist Bioscience operates in the synthetic biology space, offering products that compete directly with Absci's protein production and drug discovery platforms.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a technology that can be seen as complementary but also competitive to Absci's AI-driven drug discovery and development.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine focuses on gene editing, directly competing with Absci in the development of novel therapeutics through advanced biotechnologies.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is another key player in the gene editing field, competing with Absci in the race to develop new genetic medicines.
Beam Therapeutics
BEAM
Mkt Cap2.76B
Beam Therapeutics specializes in base editing, a form of gene editing, positioning it as a competitor in the innovative therapeutic development space alongside Absci.
Adaptive Biotechnologies
ADPT
Mkt Cap3.94B
Adaptive Biotechnologies offers immune-driven medicine solutions, competing with Absci in the broader biotech space focused on leveraging biological systems for drug discovery.
Pacific Biosciences of California
PACB
Mkt Cap357.46M
Pacific Biosciences provides sequencing solutions that can be used in drug discovery and development, competing with Absci's technology platform.
Illumina
ILMN
Mkt Cap28.82B
Illumina offers genomic sequencing technologies, which are essential for modern drug discovery and development, thus competing with Absci's integrated drug and protein production platforms.
Syros Pharmaceuticals
SYRS
Mkt Cap2,683
Syros Pharmaceuticals is engaged in drug discovery and development using gene control as a mechanism, which places it in competition with Absci's approach to creating and optimizing protein-based therapeutics.

About

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Show more...
CEO
Sean McClain
Employees
140
Country
United States
ISIN
US00091E1091

Listings

XNAS
US
ABSI
BOATS
BOATS
ABSI.BOATS

0 Comments

Share your thoughts

FAQ

What is Absci stock price today?▼
The current price of ABSI is $9.99 USD — it has increased by +12.88% in the past 24 hours. Watch Absci stock price performance more closely on the chart.
What is Absci stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Absci stocks are traded under the ticker ABSI.
Is Absci stock price growing?▼
ABSI stock has risen by +5.6% compared to the previous week, the month change is a +22.43% rise, over the last year Absci has showed a +288.72% increase.
What is Absci market cap?▼
Today Absci has the market capitalization of 1.71B
When is the next Absci earnings date?▼
Absci is going to release the next earnings report on November 17, 2026.
What were Absci earnings last quarter?▼
ABSI earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.19 USD resulting in a -9.93% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Absci revenue for the last year?▼
Absci revenue for the last year amounts to 2.8M USD.
What is Absci net income for the last year?▼
ABSI net income for the last year is -115.18M USD.
How many employees does Absci have?▼
As of August 20, 2026, the company has 140 employees.
In which sector is Absci located?▼
Absci operates in the Health & Wellness sector.
When did Absci complete a stock split?▼
Absci has not had any recent stock splits.
Where is Absci headquartered?▼
Absci is headquartered in VANCOUVER, United States.